Suppression of vascular permeability and inflammation by targeting of the transcription factor c-Jun

Conventional anti-inflammatory strategies induce multiple side effects, highlighting the need for novel targeted therapies. Here we show that knockdown of the basic-region leucine zipper protein, c-Jun, by a catalytic DNA molecule, Dz13, suppresses vascular permeability and transendothelial emigration of leukocytes in murine models of vascular permeability, inflammation, acute inflammation and rheumatoid arthritis. Treatment with Dz13 reduced vascular permeability due to cutaneous anaphylactic challenge or VEGF administration in mice. Dz13 also abrogated monocyte-endothelial cell adhesion in vitro and abolished leukocyte rolling, adhesion and extravasation in a rat model of inflammation. Dz13 suppressed neutrophil infiltration in the lungs of mice challenged with endotoxin, a model of acute inflammation. Finally, Dz13 reduced joint swelling, inflammatory cell infiltration and bone erosion in a mouse model of rheumatoid arthritis. Mechanistic studies showed that Dz13 blocks cytokine-inducible endothelial c-Jun, E-selectin, ICAM-1, VCAM-1 and VE-cadherin expression but has no effect on JAM-1, PECAM-1, p-JNK-1 or c-Fos. These findings implicate c-Jun as a useful target for anti-inflammatory therapies.

[1]  N. Davies,et al.  Review article: non‐steroidal anti‐inflammatory drug‐induced gastrointestinal permeability , 1998, Alimentary pharmacology & therapeutics.

[2]  Giuseppe Cirino,et al.  Endothelial nitric oxide synthase: the Cinderella of inflammation? , 2003, Trends in pharmacological sciences.

[3]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[4]  B. Engelhardt,et al.  Mini‐review: Transendothelial migration of leukocytes: through the front door or around the side of the house? , 2004, European journal of immunology.

[5]  P. Hordijk,et al.  Signaling in Leukocyte Transendothelial Migration , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[6]  L. Khachigian,et al.  c-Jun Regulates Vascular Smooth Muscle Cell Growth and Neointima Formation after Arterial Injury , 2002, The Journal of Biological Chemistry.

[7]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[8]  L. Khachigian,et al.  New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury , 1999, Nature Medicine.

[9]  Y. Masuho,et al.  Inhibition of angiogenesis and vascular leakiness by angiopoietin-related protein 4. , 2003, Cancer research.

[10]  R. Medford,et al.  Role of Activating Protein-1 in the Regulation of the Vascular Cell Adhesion Molecule-1 Gene Expression by Tumor Necrosis Factor-α* , 1998, The Journal of Biological Chemistry.

[11]  L. Khachigian,et al.  Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents. , 2004, Journal of the National Cancer Institute.

[12]  Napoleone Ferrara,et al.  Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. , 2002, Seminars in oncology.

[13]  S. Morony,et al.  Osteoclast Numbers in Lewis Rats with Adjuvant-induced Arthritis: Identification of Preferred Sites and Parameters for Rapid Quantitative Analysis , 2004, Veterinary pathology.

[14]  P. Wooley,et al.  Collagen arthritis--what can it teach us? , 1994, British journal of rheumatology.

[15]  M. Stemerman,et al.  Adenovirus-mediated overexpression of c-Jun and c-Fos induces intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human endothelial cells. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[16]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[17]  J. Isner,et al.  Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. , 1998, Circulation.

[18]  L. Khachigian,et al.  New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury , 1999, Nature Medicine.

[19]  K. Schuff.  Issues in the diagnosis of Cushing's syndrome for the primary care physician. , 2003, Primary care.

[20]  T. Kagari,et al.  The Importance of IL-1β and TNF-α, and the Noninvolvement of IL-6, in the Development of Monoclonal Antibody-Induced Arthritis , 2002, The Journal of Immunology.

[21]  L. Khachigian,et al.  Catalytic Oligodeoxynucleotides Define a Key Regulatory Role for Early Growth Response Factor-1 in the Porcine Model of Coronary In-Stent Restenosis , 2001, Circulation research.

[22]  L. Khachigian,et al.  Catalytic Antisense DNA Molecules Targeting Egr-1 Inhibit Neointima Formation following Permanent Ligation of Rat Common Carotid Arteries , 2002, Thrombosis and Haemostasis.

[23]  J. Gamble,et al.  Angiopoietin-1 Is an Antipermeability and Anti-Inflammatory Agent In Vitro and Targets Cell Junctions , 2000, Circulation research.

[24]  S. Grimm,et al.  Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  G. F. Joyce,et al.  A general purpose RNA-cleaving DNA enzyme. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Ronald R. Breaker,et al.  Natural and engineered nucleic acids as tools to explore biology , 2004, Nature.

[27]  T. Kagari,et al.  The importance of IL-1 beta and TNF-alpha, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. , 2002, Journal of immunology.

[28]  W. Min,et al.  TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways. , 1997, Journal of immunology.

[29]  Tom J. Parry,et al.  Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA , 1999, Nucleic Acids Res..

[30]  Lois E. H. Smith,et al.  Oxygen-induced retinopathy in the mouse. , 1994, Investigative ophthalmology & visual science.

[31]  P. Delafontaine,et al.  Nonsteroidal anti-Inflammatory drugs and cardiovascular risk. , 2004, Journal of the American College of Cardiology.

[32]  Levon M Khachigian,et al.  Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth. , 2004, Nucleic acids research.

[33]  Lawrence A. Yannuzzi,et al.  PRECLINICAL AND PHASE 1A CLINICAL EVALUATION OF AN ANTI-VEGF PEGYLATED APTAMER (EYE001) FOR THE TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION , 2002, Retina.

[34]  N. Hay,et al.  Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo , 2005, Nature Medicine.